Calcium Carbonate

Pregnancy

MotherToBaby's sheet dated 1 October 2025 says calcium carbonate used as directed and within recommended amounts is not expected to increase miscarriage, birth-defect, preterm-delivery, or low-birth-weight risk; it gives no trimester-specific outcome estimates or study designs. The sheet says excess use might increase low-birth-weight risk, but it does not provide a dose-specific estimate. Direct evidence about excess use consists mainly of case reports. Robertson (2002) described late neonatal hypocalcemia and noted that large maternal doses may be a cause. Borkenhagen et al. (2013) reported one term girl with seizures and low blood calcium after her mother took 3-6 g of calcium carbonate daily during the final four months of pregnancy. Thornton et al. (2013) reported one 6-day-old boy with low calcium-related findings after extreme third-trimester use. Ullian and Linas (1988) described one pregnancy case after calcium carbonate and calcium-containing food during hyperemesis, with high blood calcium, dehydration, reduced kidney function, and pancreatitis. A 2022 review says calcium-containing antacids at usual doses are preferred for pregnancy reflux, but also notes an older third-trimester signal for antacids as a class; it does not show that the signal was caused by calcium carbonate. A Cochrane review of routine calcium supplementation found no clear additional benefit for preventing low birth weight, but those trials do not answer the question of excessive over-the-counter antacid use. A 2026 pilot trial tested 500 mg calcium carbonate every four hours with oxytocin in 55 nulliparous women at 36 weeks or later; its main goals were feasibility and acceptability, and it was not powered for clinical outcomes. No dose-specific human outcome estimate for ordinary calcium-carbonate antacid use in each trimester was verified in the reviewed sources.

Breastfeeding

MotherToBaby says calcium is present in breast milk and that calcium carbonate at recommended amounts is unlikely to harm a nursing baby, but reports no infant outcome counts or milk-production findings. NHS SPS says there is no published evidence of calcium carbonate use during breastfeeding. It still describes use at recommended doses for heartburn or indigestion and says specific infant monitoring is usually not required, based on calcium's natural presence in milk and poor oral absorption. No direct milk-level study or exposed-infant follow-up was identified in the sources reviewed. The compatible rating reflects this specialist guidance for recommended antacid doses, while direct human evidence remains absent.

What was tested

The reviewed pregnancy evidence includes old retrospective antacid-class findings, case reports of excessive calcium-carbonate use, and a 2026 labor-induction feasibility pilot. The case reports describe individual newborns or pregnant patients, not population risk estimates. The pilot tested calcium carbonate with oxytocin during labor and was not powered to establish clinical outcome differences. The reviewed sources did not identify trimester-specific controlled studies of usual-dose calcium carbonate for heartburn or direct breastfeeding exposure studies.